Keywords: Bayer, Regorafenib, Stivarga, Colorectal cancer, FDA, USA

Early FDA approval for Bayer's Stivarga in advanced colorectal cancer

Article | 28 September 2012

Print This

The US Food and Drug Administration yesterday approved German drug major Bayer’s (BAYN: DE) Stivarga (regorafenib) to treat ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in